Bioxcel therapeutics announces fda closed its inspection of site for phase 3 tranquility ii trial for acute treatment of agitation associated with alzheimer's dementia

Fda concludes site inspection is closed under 21 c.f.r.20.64(d)(3); voluntary action indicated company believes this further supports reliability of data from tranquility ii trial of bxcl501 new haven, conn., march 03, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the u.s. food and drug administration (fda) has concluded that the inspection of a single site in its tranquility ii phase 3 trial is closed under 21 c.f.r.20.64(d)(3) and released the establishment inspection report.
BTAI Ratings Summary
BTAI Quant Ranking